刚果(金)战乱地区2018年埃博拉疫情中rVSV-ZEBOV疫苗的可接受性与满意度
研究在刚果民主共和国东部开展横断面调查,纳入90名rVSV-ZEBOV疫苗接种者和96名社区对照。83%接种者报告副作用,84%接种者愿推荐疫苗,72%未接种对照希望接种,82%受访者愿为家人接受接种。疫苗耐受性良好且社区接受度高。
要点
- rVSV-ZEBOV疫苗接种者中83%报告副作用,关节痛和皮疹分别仅7%和5%。
- 84%接种者愿推荐疫苗,72%未接种对照希望接种,82%愿为家人接受接种。
- 疫情期间该疫苗耐受性良好且社区接受度高。
核心结论
- rVSV-ZEBOV疫苗在当前刚果(金)埃博拉疫情中耐受性良好,社区接受度高。
研究设计与样本
- 横断面调查问卷,便利抽样纳入刚果(金)东部90名疫苗接种者和96名社区对照。
主要发现
- 75/90(83%)疫苗接种者报告副作用,仅5例(7%)报告关节痛、4例(5%)报告皮疹。
- 76/90(84%)接种者被归类为推荐者,6/90(7%)为贬损者。
- 69/96(72%)未接种社区对照希望在有疫苗供应时接种。
- 153/186(82%)受访者愿为家人接受疫苗接种。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The current Ebola outbreak in Eastern Democratic Republic of the Congo (DRC) is the second largest in history and the first in which the recombinant Vesicular Stomatitis Virus - Zaire Ebolavirus (rVSV-ZEBOV) vaccine has been used at scale. We assessed side-effects, satisfaction, and attitudes toward the new vaccine. METHODS: Cross-sectional survey questionnaire from a convenience sample of 90 vaccine recipients and 96 community controls in Eastern DRC. RESULTS: Side-effects were reported in 75/90 (83%) vaccine recipients but only 5 (7%) and 4 (5%) reported arthralgia and rash, respectively. 76/90 (84%) vaccinees were classified as "promoters" (would recommend vaccine to others) and 6/90 (7%) as "detractors." 69/96 (72%) of unvaccinated community controls would wish to be vaccinated if supply were available. 153/186 (82%) would accept vaccination for family members. CONCLUSIONS: The rVSV-ZEBOV vaccine was well tolerated, with high acceptability in the community during the current outbreak in the DRC.
引用
- Kasereka MC, Sawatzky J, Hawkes MT, et al. Ebola epidemic in war-torn Democratic Republic of Congo, 2018: Acceptability and patient satisfaction of the recombinant Vesicular Stomatitis Virus - Zaire Ebolavirus Vaccine. Vaccine. 2019. PMID: 30878249. doi:10.1016/j.vaccine.2019.03.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。